*
"Only" based on approved selective IL-23 inhibitors for moderately to severely active Crohn’s disease as of March 2025. Compared to Skyrizi® (risankizumab-rzaa) and Omvoh® (mirikizumab-mrkz) induction and maintenance dosing. Skyrizi® and Omvoh® are not available as SC injection for induction therapy in Crohn’s disease.1,5,6
STELARA® is indicated for the treatment of adults with moderately to severely active Crohn’s disease. For more information on STELARA®, please read the full Prescribing Information and Important Safety Information.
TREMFYA® is the ONLY approved IL-23i with SC administration from induction through maintenance*
View Dosing
TREMFYA® PEN Induction Pack
Not actual size.
*
"Only" based on approved selective IL-23 inhibitors for moderately to severely active Crohn’s disease as of March 2025. Compared to Skyrizi® (risankizumab-rzaa) and Omvoh® (mirikizumab-mrkz) induction and maintenance dosing. Skyrizi® and Omvoh® are not available as SC injection for induction in Crohn’s disease.1,5,6
Once a decision has been
made to prescribe TREMFYA®
TREMFYA withMe provides support to help your patients start and stay on TREMFYA®
References: 1. TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn’s and Colitis Organisation (ECCO); March 1-4, 2023; Copenhagen, Denmark. Poster P504. 3. Sewell GW, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J Crohns Colitis. 2022;16(suppl 2):ii3-ii19. doi: 10.1093/ecco-jcc/jjac034 4. Krueger JG, Eyerich K, Kuchroo VK, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. doi: 10.3389/fimmu.2024.1331217 5. Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie Inc. 6. Omvoh® [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. 7. Data on file. Janssen Biotech, Inc.